Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA387573
Max Phase: Preclinical
Molecular Formula: C34H46N10O3
Molecular Weight: 642.81
Molecule Type: Small molecule
Associated Items:
ID: ALA387573
Max Phase: Preclinical
Molecular Formula: C34H46N10O3
Molecular Weight: 642.81
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)NCc1ccccc1
Standard InChI: InChI=1S/C34H46N10O3/c35-27(13-7-19-40-33(36)37)30(45)44-29(21-23-15-17-26(18-16-23)25-11-5-2-6-12-25)32(47)43-28(14-8-20-41-34(38)39)31(46)42-22-24-9-3-1-4-10-24/h1-6,9-12,15-18,27-29H,7-8,13-14,19-22,35H2,(H,42,46)(H,43,47)(H,44,45)(H4,36,37,40)(H4,38,39,41)/t27-,28-,29-/m0/s1
Standard InChI Key: IIUQVWAODMBQQA-AWCRTANDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 642.81 | Molecular Weight (Monoisotopic): 642.3754 | AlogP: 1.04 | #Rotatable Bonds: 18 |
Polar Surface Area: 237.12 | Molecular Species: BASE | HBA: 6 | HBD: 10 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.31 | CX Basic pKa: 11.87 | CX LogP: 0.39 | CX LogD: -4.37 |
Aromatic Rings: 3 | Heavy Atoms: 47 | QED Weighted: 0.05 | Np Likeness Score: -0.07 |
1. Svenson J, Brandsdal BO, Stensen W, Svendsen JS.. (2007) Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect., 50 (14): [PMID:17569519] [10.1021/jm0703542] |
2. Karstad R, Isaksen G, Brandsdal BO, Svendsen JS, Svenson J.. (2010) Unnatural amino acid side chains as S1, S1', and S2' probes yield cationic antimicrobial peptides with stability toward chymotryptic degradation., 53 (15): [PMID:20608742] [10.1021/jm1006337] |
3. Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J.. (2011) In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides., 54 (7): [PMID:21401113] [10.1021/jm1015704] |
4. Karstad R, Isaksen G, Wynendaele E, Guttormsen Y, De Spiegeleer B, Brandsdal BO, Svendsen JS, Svenson J.. (2012) Targeting the S1 and S3 subsite of trypsin with unnatural cationic amino acids generates antimicrobial peptides with potential for oral administration., 55 (14): [PMID:22720778] [10.1021/jm3002058] |
Source(1):